Cell Therapy Technologies
Veterinary Mononuclear Cell Therapy
Cell Therapy Technologies
Veterinary Mononuclear Cell Therapy
PAX Advanced Therapies Mononuclear Cell Therapy Treatment
Transforming Veterinary Cell Therapy Treatment
PAX Advanced Therapies is an American biotech distribution company based on Long Island NY, specializing in Mononuclear Cells Therapy and Technology Products for animals & soon humans, connected to an international research network.
MONOcells VET® Cell Therapy:
A natural and safe cell therapy to relieve the pain of joint disease or injury, promote healing and reduce recovery time using the patient’s own blood.
Sign up for our Newsletter
Stay up-to-date with the latest news and promotions from PAX Advanced Therapies. Sign up for our newsletter today and be the first to hear about our latest news.
PAX Advanced Therapies MONOcells VET ® Cell Therapy:
Product Features
Features of MONOcells VET®
MONOcells VET ® is a simple, single use disposable that concentrates platelets using a unique filter-based technology. As blood flows through the MONOcells VET ® system, peripheral blood mononuclear cells (PBMC) are selectively captured on the surface of the filter and then back-flushed into a smaller volume, creating a PBMC concentrate. The MONOcells VET ® system has several advantages over other techniques:
No centrifuge or power supply required
·As easy to use in the field as it is in the clinic
·Gentle gravity filtration is easy on cells and platelets, creating a high-quality concentrate that is rich
in healing and growth factors
·Cost effective and efficient
·Natural cell therapy to promote healing
·Minimally invasive
·Reduces the risk of adverse reactions by the patient’s own blood
·Same day procedure
·Can be used alone or in conjunction with other treatments, depending on the patient’s needs
About PAX Advanced Therapies
Paxton Provitera, PhD
- Paxton Provitera is a U.S. Biomedical Engineer and PhD in Physiology and Biophysics. As R&D Project Manager at Pall Medical for 15 years, Paxton designed the selective filter for the concentration of peripheral blood mononuclear cells introduced in recent years as an autologous cell therapy, primarily aimed at treating critical ischemia of the lower limbs and diabetic foot. Paxton now leads Pax Advanced Therapies in developing next-generation filtration and cell separation systems and cutting-edge methods to tackle increasingly complex and ambitious biomedical challenges.